Claims for Patent: 9,169,250

Summary for Patent: 9,169,250

Title:	Compounds modulating c-fms and/or c-kit activity and uses therefor
Abstract:	Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
Inventor(s):	Zhang; Jiazhong (Burlingame, CA), Ibrahim; Prabha N. (Mountain View, CA), Bremer; Ryan (Emeryville, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	14/250,331
Patent Claims:	1. A pharmaceutical composition comprising a compound of formula: ##STR00923## and a pharmaceutically acceptable carrier, diluent or excipient. 2. The pharmaceutical composition of claim 1 in unit dosage form. 3. The pharmaceutical composition of claim 2, wherein the unit dosage form is a capsule or a tablet. 4. The pharmaceutical composition of claim 2, wherein the unit dosage form is a capsule. 5. The pharmaceutical composition of claim 2, wherein the unit dosage form is a tablet. 6. A hydrochloric acid salt of a compound of formula: ##STR00924## 7. A pharmaceutical composition comprising the hydrochloric acid salt of claim 6, and a pharmaceutically acceptable carrier, diluent or excipient. 8. The pharmaceutical composition of claim 7 in unit dosage form. 9. The pharmaceutical composition of claim 8, wherein the unit dosage form is a capsule or a tablet. 10. The pharmaceutical composition of claim 8, wherein the unit dosage form is a capsule. 11. The pharmaceutical composition of claim 8, wherein the unit dosage form is a tablet. 12. A polymorphic form of a compound of formula: ##STR00925## 13. A pharmaceutical composition comprising the polymorphic form of claim 12, and a pharmaceutically acceptable carrier, diluent or excipient. 14. The pharmaceutical composition of claim 13 in unit dosage form. 15. The pharmaceutical composition of claim 14, wherein the unit dosage form is a capsule or a tablet. 16. The pharmaceutical composition of claim 14, wherein the unit dosage form is a capsule. 17. The pharmaceutical composition of claim 14, wherein the unit dosage form is a tablet.